Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder): First interim analysis of the non-interventional study PIAZA. 6. Juni 2013 Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Teichmann, B., Harde, J., Hasskarl, J., 2013. Onkologie 36 (suppl. 7)(P797), 241. doi:10.1159/000356365 Abstract Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis. van de Water, W., Seynaeve, C., Bastiaannet, E., Markopoulos, C., Jones, S.E., Rea, D., Hasenburg, A., Putter, H., Hille, E.T.M., Paridaens, R., de Craen, A.J.M.,… Weiterlesen Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC). Welt, A., Lerchenmüller, C., Decker, T., Marschner, N., Salat, C., Hegewisch-Becker, S., 2013. Cancer Res 73 (24 Suppl)(P3-13-01). doi:10.1158/0008-5472.SABCS13-P3-13-01 Abstract… Weiterlesen